Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/213937
Title: PRMT5 IS A POTENTIAL THERAPEUTIC VULNERABILITY IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
Authors: MALINI RETHNAM
Keywords: BPDCN, PRMT5, METTL3, RNA modification, IFN signaling
Issue Date: 19-Jul-2021
Citation: MALINI RETHNAM (2021-07-19). PRMT5 IS A POTENTIAL THERAPEUTIC VULNERABILITY IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM. ScholarBank@NUS Repository.
Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic cancer that arises from malignant transformation of plasmacytoid dendritic cells (pDCs) and is predisposed to leukemic transformation. A recurrent feature of BPDCN is dysregulated MYC expression, which is associated with dependence on Protein arginine methyltransferase 5 (PRMT5). It was recently reported that BPDCN patient samples were enriched for a PRMT5 gene signature, suggesting a role for PRMT5 in BPDCN. In this thesis, the role and potential of PRMT5 as a therapeutic target in BPDCN, and how the expression of methyltransferase-like protein 3 (METTL3), a writer of m6A modification on RNA, determines BPDCN cells’ response to PRMT5 inhibition, was evaluated. Overall, the findings from this study have identified a new therapeutic target in BPDCN and uncovered a unique interconnection among PRMT5, METTL3 and interferon signaling pathway, which has not been reported in hematological malignancies like BPDCN.
URI: https://scholarbank.nus.edu.sg/handle/10635/213937
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Malini Rethnam_Thesis.pdf4.71 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

45
checked on Jan 26, 2023

Download(s)

1
checked on Jan 26, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.